Medicare Now Covers GLP-1 Weight Loss Drugs — Here's Exactly How to Get Coverage (Updated July 2026)

For the first time in Medicare's history, the program is covering GLP-1 medications specifically for weight loss. The Medicare GLP-1 Bridge Program, announced by CMS and running from July 1, 2026 through December 31, 2027, opens a door that has been locked for millions of Americans with obesity.

Why This Matters

Under the Social Security Act, Medicare has historically been prohibited from covering weight-loss drugs (Section 1861(zz)). The GLP-1 Bridge Program is a temporary administrative workaround that leverages the comorbidity exception — covering these drugs for beneficiaries who have obesity and at least one weight-related medical condition.

This covers an estimated 42 million Medicare beneficiaries with BMI over 30 who also have hypertension, type 2 diabetes, or cardiovascular disease.

Who Qualifies

To be covered under the Bridge Program, you must meet all of the following criteria:

• Enrolled in Medicare Part D — the prescription drug benefit
• BMI of 30 or higher (class I obesity or above)
• At least one weight-related comorbidity: hypertension, type 2 diabetes, heart disease, or sleep apnea
• Have a prescription from a licensed provider for either Wegovy or Zepbound

If you have a Medicare Advantage plan (Part C), your coverage may differ — many Advantage plans already offer supplemental drug benefits. Check your plan's Summary of Benefits.

What Is Covered

The Bridge Program covers two specific medications:

• Wegovy (semaglutide 2.4mg) — Novo Nordisk's weight-loss formulation. The oral pill version is also expected to be covered as formulations are added to Part D formularies.
• Zepbound (tirzepatide) — Eli Lilly's dual GIP/GLP-1 agonist, which showed 20-22% average weight loss in clinical trials.

Notably covered: the injectable forms of both drugs. The oral semaglutide (Wegovy pill, approved December 2025) and oral tirzepatide (Foundayo, approved early 2026) should be added to Part D formularies as manufacturers complete formulary update cycles.

Not covered: compounded versions of semaglutide or tirzepatide. The Bridge Program applies to FDA-approved, brand-name products only.

What You Will Pay

Your out-of-pocket cost depends on your Part D plan's formulary tier placement:

• Tier 3 (Preferred Brand): Typically $47-$100/month copay
• Tier 4 (Non-Preferred Brand): Typically $100-$200/month copay or 25-33% coinsurance
• Tier 5 (Specialty): Coinsurance of 25-33%, which at $1,350/month list price = $337-$445/month

If you qualify for Extra Help (Low Income Subsidy), your copay could be as low as $0-$11 per month. Approximately 2.5 million Medicare beneficiaries already qualify for Extra Help and may not know it.

The Prior Authorization Process

Expect prior authorization requirements. Your prescribing physician will need to submit documentation showing:

• Your current BMI (must be 30+)
• Diagnosis codes for at least one qualifying comorbidity
• Documentation of previous weight-loss attempts (most plans require evidence of diet/exercise programs)
• A letter of medical necessity outlining why a GLP-1 is appropriate for your specific case

The prior authorization decision typically takes 72 hours for standard review, or 24 hours for expedited review if your doctor certifies that waiting would seriously jeopardize your health.

Medicaid Coverage — A Different Story

Medicaid is a separate program run at the state level, and coverage varies dramatically:

• States covering GLP-1s for weight loss under Medicaid: Approximately 15 states now provide some form of coverage, typically with strict prior authorization and step-therapy requirements
• States with no coverage: Roughly 20 states explicitly exclude weight-loss medications from Medicaid formularies
• States with diabetes-only coverage: Many states cover GLP-1s when prescribed for type 2 diabetes (not weight loss) — the same drug, different diagnosis code, different coverage outcome

If your state's Medicaid program does not cover GLP-1s for weight loss, the BMI + comorbidity route through a diabetes diagnosis code remains the most practical path to coverage in those states.

What Happens After December 2027?

The Bridge Program is temporary. It is not a permanent change to Medicare policy, though advocates are pushing for legislation to make GLP-1 weight-loss coverage permanent. Several bills are currently in Congress that would amend Section 1861(zz) to allow Medicare coverage of weight-loss drugs.

If no legislation passes by December 2027, coverage will end. Patients actively taking GLP-1s under the Bridge Program could face sudden cost increases of $1,069-$1,350/month out of pocket.

This is not theoretical. The same dynamic played out with COVID-era telehealth flexibilities that are now expiring. Patients should plan their long-term treatment strategies with this timeline in mind.

What You Should Do Right Now

• Check your Part D formulary: Log in to Medicare.gov or call your plan to confirm whether Wegovy or Zepbound are on your plan's formulary and at what tier
• Talk to your doctor about prior authorization: If you have BMI 30+ and a qualifying comorbidity, the paperwork window is open now
• Apply for Extra Help if eligible: Income limits are generous (up to 150% of the federal poverty level). Many beneficiaries qualify and are not enrolled
• If coverage is denied, appeal: You have the right to a redetermination within 60 days. The approval rate for Part D appeals on GLP-1 medications has been climbing as more plans recognize these drugs as standard-of-care